CVS Health Sees Unusually High Options Volume (NYSE:CVS)

CVS Health Corporation (NYSE:CVS) was the recipient of unusually large options trading on Tuesday. Traders bought 30,223 call options on the stock. This is an increase of approximately 52% compared to the typical daily volume of 19,874 call options.

CVS Health Price Performance

CVS traded up $1.72 during trading on Tuesday, reaching $71.86. 7,718,509 shares of the company traded hands, compared to its average volume of 8,877,940. CVS Health has a 12-month low of $58.35 and a 12-month high of $85.15. The firm has a fifty day simple moving average of $76.45 and a 200 day simple moving average of $77.76. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84. The company has a market cap of $91.42 billion, a P/E ratio of 52.07, a PEG ratio of 0.73 and a beta of 0.49.

CVS Health (NYSE:CVS) last issued its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. The firm had revenue of $105.69 billion during the quarter, compared to analyst estimates of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. CVS Health’s revenue for the quarter was up 8.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, equities analysts forecast that CVS Health will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd will be paid a $0.665 dividend. The ex-dividend date of this dividend is Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 3.7%. CVS Health’s payout ratio is presently 192.75%.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Unusual bullish options flow — investors bought ~30,223 call options on Tuesday (about +52% vs. typical daily call volume), signaling amplified bullish speculative or hedging interest that can boost near-term buying pressure.
• Positive Sentiment: Retail expansion plan — CVS plans roughly 60 store openings in 2026 (including nearly 20 pharmacy-only sites), reversing years of net closures and indicating management focus on growth and improved retail margins. CVS to Open More Stores in 2026 Than It Shuts in Retail Turnaround
• Positive Sentiment: Execution: first pharmacy-only store opened in Chicago as rollout begins, giving investors tangible proof the strategy is underway. CVS Pharmacy® celebrates opening of first pharmacy-only location in Chicago
• Positive Sentiment: Service expansion opportunity — industry reports list CVS among leaders in the growing chemotherapy-at-home services market, highlighting an ancillary growth avenue beyond retail and PBM businesses. Trends and Opportunities in the Chemotherapy-At-Home Services Market, 2026-2030
• Neutral Sentiment: Analyst view: Piper Sandler trimmed its price target slightly from $101 to $99 but kept an “overweight” rating—still implying significant upside vs. current levels, supporting positive analyst sentiment overall. Benzinga
• Neutral Sentiment: Earnings watch: inclusion in Zacks’ screen of medical stocks that could beat earnings keeps focus on upcoming results and the Earnings ESP tool for short-term analyst surprises. These 2 Medical Stocks Could Beat Earnings
• Negative Sentiment: Regulatory/legal risk: reports note a proposed FTC settlement related to insulin pricing — resolution terms could create cash or reputational impacts depending on settlement size and conditions. CVS Health (CVS) Reaches Proposed FTC Settlement on Insulin Pricing
• Negative Sentiment: Fundamental scrutiny: broader articles flag large-cap names (including CVS in some coverage) for growth/fundamental questions, which can weigh on sentiment if investors focus on valuation or margin sustainability. 3 Large-Cap Stocks with Questionable Fundamentals

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Wolfe Research reduced their target price on shares of CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a report on Monday, March 2nd. Argus dropped their price target on shares of CVS Health from $91.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, January 28th. Bank of America reduced their price objective on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a research note on Tuesday, January 27th. JPMorgan Chase & Co. raised their price objective on shares of CVS Health from $93.00 to $101.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Finally, Leerink Partners reaffirmed an “outperform” rating and issued a $98.00 target price on shares of CVS Health in a report on Thursday, March 5th. Twenty investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, CVS Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.95.

Institutional Investors Weigh In On CVS Health

Several large investors have recently bought and sold shares of the business. National Pension Service increased its position in CVS Health by 3.1% during the third quarter. National Pension Service now owns 3,999,622 shares of the pharmacy operator’s stock valued at $301,532,000 after acquiring an additional 119,189 shares during the last quarter. Kingsview Wealth Management LLC grew its holdings in CVS Health by 316.2% during the 3rd quarter. Kingsview Wealth Management LLC now owns 104,432 shares of the pharmacy operator’s stock valued at $7,873,000 after purchasing an additional 79,340 shares during the last quarter. AE Wealth Management LLC raised its position in CVS Health by 6.2% in the 3rd quarter. AE Wealth Management LLC now owns 257,204 shares of the pharmacy operator’s stock worth $19,391,000 after purchasing an additional 14,983 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in CVS Health by 11.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 225,116 shares of the pharmacy operator’s stock worth $16,971,000 after purchasing an additional 22,653 shares during the last quarter. Finally, Alpha Omega Wealth Management LLC grew its stake in shares of CVS Health by 12.3% during the third quarter. Alpha Omega Wealth Management LLC now owns 149,902 shares of the pharmacy operator’s stock valued at $11,301,000 after buying an additional 16,418 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.